본문 바로가기
KERD
논문KCI 등재후보

Uric acid and cardiometabolic diseases

성기철|Lee Seung Jae|오병길
대한고혈압학회 (The Korean Society of Hypertension)|2020.07|Clinical Hypertension|제26권 제3호|pp. 59-65|DOI 10.1186/s40885-020-00146-y

1

조회

0

다운로드

1

인용

0

참고문헌

키워드

Metabolic syndromeUric acidCardiovascular diseaseCardiometabolic disease

초록

Hyperuricemia, which has been considered as a cause of gout and nephrolithiasis has recently been suggested to be associated with hypertension, coronary heart disease, heart failure, atrial fibrillation, insulin resistance, and nonalcoholic fatty liver disease. Several clinical and experimental studies have supported uric acid (UA) as an independent risk factor for predicting disease development along with the traditional risk factors. The mechanism by which UA causes cardiometabolic disease has not been fully elucidated to date; however, it has been explained by several hypotheses such as oxidative stress, reduced nitric oxide bioavailability, inflammation, endothelial dysfunction, and so on. Although evidence of the preventive and therapeutic effects of UA lowering therapy on cardiometabolic diseases is still insufficient, it is expected to be considered as a new treatment strategy for such diseases through additional, carefully designed, large-scale clinical studies.

Abstract

Hyperuricemia, which has been considered as a cause of gout and nephrolithiasis has recently been suggested to be associated with hypertension, coronary heart disease, heart failure, atrial fibrillation, insulin resistance, and nonalcoholic fatty liver disease. Several clinical and experimental studies have supported uric acid (UA) as an independent risk factor for predicting disease development along with the traditional risk factors. The mechanism by which UA causes cardiometabolic disease has not been fully elucidated to date; however, it has been explained by several hypotheses such as oxidative stress, reduced nitric oxide bioavailability, inflammation, endothelial dysfunction, and so on. Although evidence of the preventive and therapeutic effects of UA lowering therapy on cardiometabolic diseases is still insufficient, it is expected to be considered as a new treatment strategy for such diseases through additional, carefully designed, large-scale clinical studies.

참고문헌 (111)

  1. El Ridi R, "Physiological functions and pathogenic potential of uric acid : a review", J Adv Res, 8, pp.487~493 (2017)
  2. Chaudhary K, "Uric acid-key ingredient in the recipe for cardiorenal metabolic syndrome", Cardiorenal Med, 3, pp.208~220 (2013)
  3. Choi HK, "Purine-rich foods, dairy and protein intake, and the risk of gout in men", N Engl J Med, 350, pp.1093~1103 (2004)
  4. Faller J, "Ethanol-induced hyperuricemia : evidence for increased urate production by activation of adenine nucleotide turnover", N Engl J Med, 307, pp.1598~1602 (1982)
  5. Perez-Pozo SE, "Excessive fructose intake induces the features of metabolic syndrome in healthy adult men : role of uric acid in the hypertensive response", Int J Obes, 34, pp.454~461 (2010)
  6. Johnson RJ, "Uric acid, evolution and primitive cultures", Semin Nephrol, 25, pp.3~8 (2005)
  7. Dalbeth N, "Gout", Lancet, 388, pp.2039~2052 (2016)
  8. Riches PL, "Recent insights into the pathogenesis of hyperuricaemia and gout", Hum Mol Genet, 18, pp.R177~R184 (2009)
  9. Maiuolo J, "Regulation of uric acid metabolism and excretion", Int J Cardiol, 213, pp.8~14 (2016)
  10. Khan SR, "Kidney stones", Nat Rev Dis Primers, 2, pp.16008~ (2016)
  11. Abeles AM, "Hyperuricemia, gout, and cardiovascular disease : an update", Curr Rheumatol Rep, 17, pp.13~ (2015)
  12. Singh G, "Gout and hyperuricaemia in the USA : prevalence and trends", Rheumatology(Oxford), 58(12), pp.2177~2180 (2019)
  13. Kim JW, "Prevalence and incidence of gout in Korea : data from the national health claims database 2007-2015", Rheumatol Int, 37, pp.1499~1506 (2017)
  14. Liu R, "Prevalence of hyperuricemia and gout in Mainland China from 2000 to 2014 : a systematic review and meta-analysis", Biomed Res Int, 2015, pp.762820~ (2015)
  15. Kuo CF, "Rising burden of gout in the UK but continuing suboptimal management : a nationwide population study", Ann Rheum Dis, 74, pp.661~667 (2015)
  16. Bardin T, "Prevalence of gout in the adult population of France", Arthritis Care Res(Hoboken), 68, pp.261~266 (2016)
  17. Davies KJ, "Uric acid-iron ion complexes. A new aspect of the antioxidant functions of uric acid", Biochem J, 235, pp.747~754 (1986)
  18. Nieto FJ, "Uric acid and serum antioxidant capacity: a reaction to atherosclerosis?", Atherosclerosis, 148, pp.131~139 (2000)
  19. Waring WS, "Systemic uric acid administration increases serum antioxidant capacity in healthy volunteers", J Cardiovasc Pharmacol, 38, pp.365~371 (2001)
  20. Johnson RJ, "Lessons from comparative physiology: could uric acid represent a physiologic alarm signal gone awry in western society?", J Comp Physiol B, 179, pp.67~76 (2009)
  21. Borghi C, "Serum uric acid levels are associated with cardiovascular risk score : a post hoc analysis of the EURIKA study", Int J Cardiol, 253, pp.167~173 (2018)
  22. Fang J, "Serum uric acid and cardiovascular mortality the NHANES I epidemiologic follow-up study, 1971-1992. National Health and Nutrition Examination Survey", JAMA, 283, pp.2404~2410 (2000)
  23. Yoo TW, "Relationship between serum uric acid concentration and insulin resistance and metabolic syndrome", Circ J, 69, pp.928~933 (2005)
  24. Jae Woong Lee, "Serum Uric Acid as a Predictor for the Development of Nonalcoholic Fatty Liver Disease in Apparently Healthy Subjects: A 5-Year Retrospective Cohort Study", Gut and Liver, 4(3), pp.378~383 (2010), 거트앤리버 소화기연관학회협의회
  25. Chonchol M, "Relationship of uric acid with progression of kidney disease", Am J Kidney Dis, 50, pp.239~247 (2007)
  26. Kuwabara M, "Asymptomatic hyperuricemia without comorbidities predicts cardiometabolic diseases : five-year Japanese cohort study", Hypertension, 69, pp.1036~1044 (2017)
  27. Wang J, "Hyperuricemia and risk of incident hypertension : a systematic review and meta-analysis of observational studies", PLoS One, 9, pp.e114259~ (2014)
  28. Buzas R, "Serum uric acid and arterial hypertension-data from Sephar III survey", PLoS One, 13, pp.e0199865~ (2018)
  29. Leiba A, "Uric acid levels within the normal range predict increased risk of hypertension : a cohort study", J Am Soc Hypertens, 9, pp.600~609 (2015)
  30. Sung KC, "Baseline and change in uric acid concentration over time are associated with incident hypertension in large Korean cohort", Am J Hypertens, 30, pp.42~50 (2017)
  31. 이재중, "Relationship between uric acid and blood pressure in different age groups", Clinical Hypertension, 21(13), pp.1~7 (2015), 대한고혈압학회[DOI]
  32. Longo-Mbenza B, "Is hyperuricemia a risk factor of stroke and coronary heart disease among Africans?", Int J Cardiol, 71, pp.17~22 (1999)
  33. De Becker B, "Uric acid and hypertension : a focused review and practical recommendations", J Hypertens, 37, pp.878~883 (2019)
  34. Khosla UM, "Hyperuricemia induces endothelial dysfunction", Kidney Int, 67, pp.1739~1742 (2005)
  35. Chao HH, "Uric acid stimulates endothelin-1 gene expression associated with NADPH oxidase in human aortic smooth muscle cells", Acta Pharmacol Sin, 29, pp.1301~1312 (2008)
  36. Yu MA, "Oxidative stress with an activation of the renin-angiotensin system in human vascular endothelial cells as a novel mechanism of uric acid-induced endothelial dysfunction", J Hypertens, 28, pp.1234~1242 (2010)
  37. Corry DB, "Uric acid stimulates vascular smooth muscle cell proliferation and oxidative stress via the vascular renin-angiotensin system", J Hypertens, 26, pp.269~275 (2008)
  38. DeBosch BJ, "Early-onset metabolic syndrome in mice lacking the intestinal uric acid transporter SLC2A9", Nat Commun, 5, pp.4642~ (2014)
  39. Neogi T, "Clinical practice", Gout. N Engl J Med, 364, pp.443~452 (2011)
  40. Parsa A, "Genotype-based changes in serum uric acid affect blood pressure", Kidney Int, 81, pp.502~507 (2012)
  41. Mallamaci F, "A polymorphism in the major gene regulating serum uric acid associates with clinic SBP and the white-coat effect in a family-based study", J Hypertens, 32, pp.1621~1628 (2014)
  42. Nowbar AN, "Mortality from ischemic heart disease", Circ Cardiovasc Qual Outcomes, 12, pp.e005375~ (2019)
  43. Okura T, "Elevated serum uric acid is an independent predictor for cardiovascular events in patients with severe coronary artery stenosis : subanalysis of the Japanese Coronary Artery Disease(JCAD)study", Circ J, 73, pp.885~891 (2009)
  44. Krishnan E, "Hyperuricemia and the risk for subclinical coronary atherosclerosis--data from a prospective observational cohort study", Arthritis Res Ther, 13, pp.R66~ (2011)
  45. Bos MJ, "Uric acid is a risk factor for myocardial infarction and stroke : the Rotterdam study", Stroke, 37, pp.1503~1507 (2006)
  46. Zuo T, "Hyperuricemia and coronary heart disease mortality : a meta-analysis of prospective cohort studies", BMC Cardiovasc Disord, 16, pp.207~ (2016)
  47. Kuo CF, "Significance of serum uric acid levels on the risk of all-cause and cardiovascular mortality", Rheumatology(Oxford), 52, pp.127~134 (2013)
  48. Kim SY, "Hyperuricemia and coronary heart disease : a systematic review and meta-analysis", Arthritis Care Res(Hoboken), 62, pp.170~180 (2010)
  49. Ioachimescu AG, "Serum uric acid is an independent predictor of all-cause mortality in patients at high risk of cardiovascular disease : a preventive cardiology information system(PreCIS)database cohort study", Arthritis Rheum, 58, pp.623~630 (2008)
  50. Ndrepepa G, "Association of uric acid with mortality in patients with stable coronary artery disease", Metabolism, 61, pp.1780~1786 (2012)
  51. Wang R, "Elevated serum uric acid and risk of cardiovascular or all-cause mortality in people with suspected or definite coronary artery disease : a meta-analysis", Atherosclerosis, 254, pp.193~199 (2016)
  52. Kang DH, "Uric acid-induced C-reactive protein expression : implication on cell proliferation and nitric oxide production of human vascular cells", J Am Soc Nephrol, 16, pp.3553~3562 (2005)
  53. Kanellis J, "Uric acid stimulates monocyte chemoattractant protein-1 production in vascular smooth muscle cells via mitogen-activated protein kinase and cyclooxygenase-2", Hypertension, 41, pp.1287~1293 (2003)
  54. Fuster V, "The pathogenesis of coronary artery disease and the acute coronary syndromes(1)", N Engl J Med, 326, pp.242~250 (1992)
  55. George J, "The role of urate and xanthine oxidase inhibitors in cardiovascular disease", Cardiovasc Ther, 26, pp.59~64 (2008)
  56. Grimaldi-Bensouda L, "Impact of allopurinol on risk of myocardial infarction", Ann Rheum Dis, 74, pp.836~842 (2015)
  57. Wheeler JG, "Serum uric acid and coronary heart disease in 9, 458 incident cases and 155, 084 controls : prospective study and meta-analysis", PLoS Med, 2, pp.e76~ (2005)
  58. Cheong E, "Association between serum uric acid and cardiovascular mortality and all-cause mortality: a cohort study", J Hypertens, 35(Suppl 1), pp.S3~S9 (2017)
  59. Li X, "Serum uric acid levels and multiple health outcomes : umbrella review of evidence from observational studies, randomised controlled trials, and Mendelian randomisation studies", BMJ, 357, pp.j2376~ (2017)
  60. Keenan T, "Causal assessment of serum urate levels in cardiometabolic diseases through a Mendelian randomization study", J Am Coll Cardiol, 67, pp.407~416 (2016)
  61. Hamaguchi S, "Hyperuricemia predicts adverse outcomes in patients with heart failure", Int J Cardiol, 151, pp.143~147 (2011)
  62. Thanassoulis G, "Gout, allopurinol use, and heart failure outcomes", Arch Intern Med, 170, pp.1358~1364 (2010)
  63. Doehner W, "Uric acid in cachectic and noncachectic patients with chronic heart failure : relationship to leg vascular resistance", Am Heart J, 141, pp.792~799 (2001)
  64. Leyva F, "Serum uric acid as an index of impaired oxidative metabolism in chronic heart failure", Eur Heart J, 18, pp.858~865 (1997)
  65. Amin A, "Serum uric acid levels correlate with filling pressures in systolic heart failure", Congest Heart Fail, 17, pp.80~84 (2011)
  66. Cicoira M, "Elevated serum uric acid levels are associated with diastolic dysfunction in patients with dilated cardiomyopathy", Am Heart J, 143, pp.1107~1111 (2002)
  67. Anker SD, "Uric acid and survival in chronic heart failure : validation and application in metabolic, functional, and hemodynamic staging", Circulation, 107, pp.1991~1997 (2003)
  68. Ekundayo OJ, "Association between hyperuricemia and incident heart failure among older adults : a propensity-matched study", Int J Cardiol, 142, pp.279~287 (2010)
  69. Holme I, "Uric acid and risk of myocardial infarction, stroke and congestive heart failure in 417, 734 men and women in the Apolipoprotein MOrtality RISk study(AMORIS)", J Intern Med, 266, pp.558~570 (2009)
  70. Wu AH, "Uric acid level and allopurinol use as risk markers of mortality and morbidity in systolic heart failure", Am Heart J, 160, pp.928~933 (2010)
  71. Tamariz L, "Uric acid as a predictor of all-cause mortality in heart failure : a meta-analysis", Congest Heart Fail, 17, pp.25~30 (2011)
  72. Huang H, "Uric acid and risk of heart failure : a systematic review and meta-analysis", Eur J Heart Fail, 16, pp.15~24 (2014)
  73. Krishnan E, "Hyperuricemia and incident heart failure", Circ Heart Fail, 2, pp.556~562 (2009)
  74. Wannamethee SG, "Serum uric acid as a potential marker for heart failure risk in men on antihypertensive treatment : the British regional heart study", Int J Cardiol, 252, pp.187~192 (2018)
  75. Kanbay M, "The role of uric acid in the pathogenesis of human cardiovascular disease", Heart, 99, pp.759~766 (2013)
  76. Hare JM, "Uric acid predicts clinical outcomes in heart failure : insights regarding the role of xanthine oxidase and uric acid in disease pathophysiology", Circulation, 107, pp.1951~1953 (2003)
  77. Berry CE, "Xanthine oxidoreductase and cardiovascular disease : molecular mechanisms and pathophysiological implications", J Physiol, 555, pp.589~606 (2004)
  78. Reyes AJ, "The increase in serum uric acid concentration caused by diuretics might be beneficial in heart failure", Eur J Heart Fail, 7, pp.461~467 (2005)
  79. Doehner W, "Effects of xanthine oxidase inhibition with allopurinol on endothelial function and peripheral blood flow in hyperuricemic patients with chronic heart failure : results from 2 placebo-controlled studies", Circulation, 105, pp.2619~2624 (2002)
  80. Xu X, "Xanthine oxidase inhibition with febuxostat attenuates systolic overload-induced left ventricular hypertrophy and dysfunction in mice", J Card Fail, 14, pp.746~753 (2008)
  81. Givertz MM, "Effects of xanthine oxidase inhibition in hyperuricemic heart failure patients : the xanthine oxidase inhibition for hyperuricemic heart failure patients(EXACT-HF)study", Circulation, 131, pp.1763~1771 (2015)
  82. Hare JM, "Impact of oxypurinol in patients with symptomatic heart failure. Results of the OPT-CHF study", J Am Coll Cardiol, 51, pp.2301~2309 (2008)
  83. Valbusa F, "Relation of elevated serum uric acid levels to incidence of atrial fibrillation in patients with type 2 diabetes mellitus", Am J Cardiol, 112, pp.499~504 (2013)
  84. Tamariz L, "Association between serum uric acid and atrial fibrillation : a systematic review and meta-analysis", Heart Rhythm, 11, pp.1102~1108 (2014)
  85. Zhang CH, "Association between serum uric acid levels and atrial fibrillation risk", Cell Physiol Biochem, 38, pp.1589~1595 (2016)
  86. study), "Am J Cardiol", 2011, 1272~1276
  87. Kwon CH, "Uric acid and risk of atrial fibrillation in the Korean general population", Circ J, 82, pp.2728~2735 (2018)
  88. Prasad M, "Uric acid is associated with inflammation, coronary microvascular dysfunction, and adverse outcomes in postmenopausal women", Hypertension, 69, pp.236~242 (2017)
  89. Hak AE, "Menopause, postmenopausal hormone use and serum uric acid levels in US women--the third national health and nutrition examination survey", Arthritis Res Ther, 10, pp.R116~ (2008)
  90. Maharani N, "Hyperuricemia and atrial fibrillation", Int Heart J, 57, pp.395~399 (2016)
  91. Iwasaki YK, "Atrial fibrillation pathophysiology : implications for management", Circulation, 124, pp.2264~2274 (2011)
  92. Hu YF, "Inflammation and the pathogenesis of atrial fibrillation", Nat Rev Cardiol, 12, pp.230~243 (2015)
  93. Dudley SC Jr, "Atrial fibrillation increases production of superoxide by the left atrium and left atrial appendage : role of the NADPH and xanthine oxidases", Circulation, 112, pp.1266~1273 (2005)
  94. Reaven GM, "Banting lecture 1988. Role of insulin resistance in human disease", Diabetes, 37, pp.1595~1607 (1988)
  95. Expert Panel on Detection E, Treatment of High Blood Cholesterol in A, "Executive summary of the third report of the National Cholesterol Education Program(NCEP)expert panel on detection, evaluation, and treatment of high blood cholesterol in adults(Adult Treatment Panel III)", JAMA, 285, pp.2486~2497 (2001)
  96. Einhorn D, "American College of Endocrinology position statement on the insulin resistance syndrome", Endocr Pract, 9, pp.237~252 (2003)
  97. Alberti KG, "The metabolic syndrome--a new worldwide definition", Lancet, 366, pp.1059~1062 (2005)
  98. Alberti KG, "Harmonizing the metabolic syndrome : a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity", Circulation, 120, pp.1640~1645 (2009)
  99. National Cholesterol Education Program Expert Panel on Detection E, Treatment of High Blood Cholesterol in A, "Third report of the National Cholesterol Education Program(NCEP)expert panel on detection, evaluation, and treatment of high blood cholesterol in adults(Adult Treatment Panel III)final report", Circulation, 106, pp.3143~3421 (2002)
  100. Wang G, "Raison d’etre of insulin resistance : the adjustable threshold hypothesis", J R Soc Interface, 11, pp.20140892~ (2014)
  101. Facchini F, "Relationship between resistance to insulin-mediated glucose uptake, urinary uric acid clearance, and plasma uric acid concentration", JAMA, 266, pp.3008~3011 (1991)
  102. Takir M, "Lowering uric acid with allopurinol improves insulin resistance and systemic inflammation in asymptomatic hyperuricemia", J Investig Med, 63, pp.924~929 (2015)
  103. Choi YJ, "Uric acid induces endothelial dysfunction by vascular insulin resistance associated with the impairment of nitric oxide synthesis", FASEB J, 28, pp.3197~3204 (2014)
  104. Baldwin W, "Hyperuricemia as a mediator of the proinflammatory endocrine imbalance in the adipose tissue in a murine model of the metabolic syndrome", Diabetes, 60, pp.1258~1269 (2011)
  105. Angulo P, "Nonalcoholic fatty liver disease", N Engl J Med, 346, pp.1221~1231 (2002)
  106. Jensen T, "Increased serum uric acid over five years is a risk factor for developing fatty liver", Sci Rep, 8, pp.11735~ (2018)
  107. Zhou Y, "High serum uric acid and risk of nonalcoholic fatty liver disease : a systematic review and meta-analysis", Clin Biochem, 49, pp.636~642 (2016)
  108. Wan X, "Uric acid regulates hepatic steatosis and insulin resistance through the NLRP3 inflammasomedependent mechanism", J Hepatol, 64, pp.925~932 (2016)
  109. Xu C, "Xanthine oxidase in nonalcoholic fatty liver disease and hyperuricemia : one stone hits two birds", J Hepatol, 62, pp.1412~1419 (2015)
  110. Choi YJ, "Uric acid induces fat accumulation via generation of endoplasmic reticulum stress and SREBP-1c activation in hepatocytes", Lab Investig, 94, pp.1114~1125 (2014)
  111. Zhu Y, "High uric acid directly inhibits insulin signalling and induces insulin resistance", Biochem Biophys Res Commun, 447, pp.707~714 (2014)

관련 논문AI추천

Role of asymptomatic hyperuricemia in the progression of chronic kidney disease and cardiovascular diseaseDong Sun, Fan Yang, Yousuf Waheed대한내과학회 · The Korean Journal of Internal Medicine2021 · 제36권 제6호Potential Role of Uric Acid as a Risk Factor for Cardiovascular Disease강덕희대한내과학회 · The Korean Journal of Internal Medicine2010 · 제25권 제1호Renal effects of uric acid: hyperuricemia and hypouricemiaJong-Ho Lee, Jung Hwan Park, Young-Il Jo대한내과학회 · The Korean Journal of Internal Medicine2020 · 제35권 제6호Association Between Serum Uric Acid Level and Metabolic Syndrome서일, 김현창, 오선민, 이주미, 조혜민, 최동필대한예방의학회 · 예방의학회지2012 · 제45권 제3호Hyperuricemia and Urologic Disease민승기, 조인창대한요로생식기감염학회 · Urogenital Tract Infection2017 · 제12권 제3호Serum Uric Acid Level and the Incidence of Metabolic Syndrome in Middle-aged Korean Men: A 5-Year Follow-up Study류재홍, 박성근, 이종근, 최중명대한예방의학회 · 예방의학회지2014 · 제47권 제6호

이 간행물의 다른 논문 (6건)

Renal artery stenosis presenting as preeclampsiaOmar Michael Brandon, Aung Win, Maharaj Satish, Kogler Williampp. 8-12Zonulin as marker of pregnancy induced hypertension: a case control studyBawah Ahmed Tijani, Ngambire Lincoln Toamsoma, Yeboah Francis Agyemang, Tornyi Henry, Seini Mohammed Mustaphapp. 13-19Highlights of the 2018 Chinese hypertension guidelinesLiu Jingpp. 20-25Is the use of RAS inhibitors safe in the current era of COVID-19 pandemic?Korean Society of Hypertension, 김광일, 유승기, 손일석, 박성하, 정욱진, 이해영, 조은주, 김현창, 김주한, 편욱범, 신진호, 성기철, 김대희, 임상현pp. 26-30Usefulness of waist-to-height ratio in screening incident hypertension among Japanese community-dwelling middle-aged and elderly individualsNinomiya Daisuke, Akase Taichi, Kawamoto Ryuichi, Kikuchi Asuka, Kumagi Terupp. 31-39
원문 보기